| 2025-07-07 | +25.6% | legal | Seeking Alpha | KalVista Pharmaceuticals rises after FDA nod for Ekterly |
| 2025-07-07 | +25.6% | legal | SEC EDGAR | KALV 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-07-07 | +25.6% | legal | Business Wire | KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire |
| 2025-07-07 | +25.6% | legal | Reuters | US FDA approves KalVista's oral swelling disorder drug, shares rise - Reuters |
| 2025-07-07 | +25.6% | legal | Stock Titan | KALV SEC Filings - Kalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2022-12-27 | +23.4% | legal | SEC EDGAR | KALV 8-K: 1.01 and (SEC Filing) |
| 2025-11-11 | +22.2% | earnings | Seeking Alpha | KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript |
| 2026-03-25 | +16.4% | earnings | GuruFocus.com | KalVista Pharmaceuticals Inc (KALV) Q4 2025 Earnings Call Highlights: Strong Launch of EKTERLY ... |
| 2026-03-25 | +16.4% | earnings | MarketBeat | KalVista Pharmaceuticals Q4 Earnings Call Highlights |
| 2026-03-25 | +16.4% | news | MT Newswires | KalVista Pharmaceuticals Narrows Net Loss Over Last 8 Months of 2025 |
| 2026-03-25 | +16.4% | earnings | Seeking Alpha | KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript |
| 2026-03-25 | +16.4% | earnings | Seeking Alpha | KalVista Pharmaceuticals beats Q4 topline estimates |
| 2026-03-25 | +16.4% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2026-03-25 | +16.4% | earnings | Stock Titan | EKTERLY drives $49.1M revenue as KalVista (Nasdaq: KALV) reports net loss - Stock Titan |
| 2026-03-26 | +16.2% | earnings | Moby | KalVista Pharmaceuticals, Inc. Q1 2025 Earnings Call Summary |
| 2026-03-26 | +16.2% | earnings | simplywall.st | KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative - simplywall.st |
| 2025-04-08 | -14.7% | legal | SEC EDGAR | KALV 8-K: 1.01, 7.01 (SEC Filing) |
| 2024-03-11 | -14.0% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-07-25 | -13.4% | news | Seeking Alpha | KalVista, Biogen, Ionis get EU positive opinions for key drugs |
| 2025-12-04 | +11.8% | analyst | Investor's Business Daily | KalVista Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily |
| 2024-09-10 | -11.2% | legal | SEC EDGAR | KALV 8-K: 5.02, 7.01 (SEC Filing) |
| 2023-12-07 | -10.2% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2021-06-07 | +10.0% | legal | SEC EDGAR | KALV 8-K: 8.01 and (SEC Filing) |
| 2025-09-11 | -9.8% | earnings | Seeking Alpha | KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript |
| 2025-09-11 | -9.8% | earnings | Seeking Alpha | KalVista Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation |
| 2025-09-11 | -9.8% | earnings | Seeking Alpha | KalVista Pharmaceuticals GAAP EPS of -$1.12 misses by $0.17, revenue of $1.43M misses by $0.66M |
| 2025-09-11 | -9.8% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-09-11 | -9.8% | news | Business Wire | KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results - Business Wire |
| 2025-09-11 | -9.8% | earnings | Seeking Alpha | KalVista Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:KALV) 2025-09-11 - Seeking Alpha |
| 2022-12-08 | +9.8% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2024-02-13 | -9.7% | legal | SEC EDGAR | KALV 8-K: 7.01, 8.01 (SEC Filing) |
| 2022-07-07 | +9.2% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-07-10 | -9.1% | earnings | Seeking Alpha | KalVista Pharmaceuticals GAAP EPS of -$3.69 |
| 2025-07-10 | -9.1% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-09-12 | -8.5% | earnings | Yahoo Finance | KalVista Pharmaceuticals Inc (KALV) Q1 2026 Earnings Call Highlights: EKTERLY Launch Drives ... - Yahoo Finance |
| 2025-10-06 | -7.8% | legal | SEC EDGAR | KALV 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-03-10 | -7.6% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-11-18 | -7.3% | news | Yahoo Finance | Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - Yahoo Finance |
| 2023-03-09 | -7.2% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2026-04-07 | -7.1% | earnings | Seeking Alpha | KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive |
| 2026-04-07 | -7.1% | earnings | Seeking Alpha | KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive (KALV) - Seeking Alpha |
| 2025-07-27 | -6.9% | analyst | Seeking Alpha | KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) |
| 2025-07-27 | -6.9% | analyst | Seeking Alpha | KalVista's EKTERLY Faces Shrinking Market, Oral Competitor Threat (Downgrade) (KALV) - Seeking Alpha |
| 2026-04-21 | -6.6% | earnings | MarketBeat | KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $193,101.00 in Stock - MarketBeat |
| 2026-04-21 | -6.6% | earnings | MarketBeat | KalVista Pharmaceuticals (NASDAQ:KALV) Cut to Hold at Wall Street Zen - MarketBeat |
| 2026-04-21 | -6.6% | earnings | MarketBeat | KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $54,310.92 in Stock - MarketBeat |
| 2026-04-21 | -6.6% | earnings | MarketBeat | KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells $37,649.64 in Stock - MarketBeat |
| 2025-09-24 | -6.3% | news | Seeking Alpha | KalVista to offer $110M in convertible notes; shares down 10% |
| 2025-09-19 | -6.3% | news | Seeking Alpha | KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs |
| 2022-03-07 | +6.3% | legal | SEC EDGAR | KALV 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-05-12 | -6.2% | legal | SEC EDGAR | KALV 8-K: 5.02 (SEC Filing) |
| 2025-04-02 | +5.8% | news | Stock Titan | KalVista Strengthens Team with Strategic 87,000-Share Option Grant Package - Stock Titan |
| 2026-04-17 | +5.7% | news | GuruFocus | KalVista Pharmaceuticals (KALV) Leads Short Interest Among Small-Cap Stocks - GuruFocus |
| 2023-07-10 | -5.7% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-07-08 | +5.6% | legal | Seeking Alpha | KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning |
| 2024-11-05 | -5.6% | news | BioSpace | KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - BioSpace |
| 2024-02-16 | -5.5% | legal | SEC EDGAR | KALV 8-K: 1.01, 2.02, 8.01 (SEC Filing) |
| 2025-07-28 | -5.4% | news | Yahoo Finance | KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency - Yahoo Finance |
| 2025-09-02 | +5.4% | earnings | Quiver Quantitative | KALVISTA PHARMACEUTICALS Earnings Preview: Recent $KALV Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative |
| 2026-02-10 | +5.3% | news | Seeking Alpha | Top Quant rated bullish small cap stocks among companies with high short interest |
| 2024-04-22 | -5.2% | legal | SEC EDGAR | KALV 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-08-08 | -5.2% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for KalVista Pharmaceuticals (KALV) - Zacks Investment Research |
| 2026-03-12 | -5.1% | news | Seeking Alpha | KalVista Pharmaceuticals: Has Potential But With Caveats |
| 2026-03-12 | -5.1% | news | Seeking Alpha | KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha |
| 2024-11-04 | +5.0% | legal | SEC EDGAR | KALV 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2024-11-04 | +5.0% | legal | SEC EDGAR | KALV 8-K: 1.01, 2.03, 7.01 (SEC Filing) |
| 2026-03-28 | -4.7% | news | Xã Thanh Hà | Is KalVista Pharmaceuticals (KALV) Stock Rebounding | Price at $19.98, Up 3.04% - Expert Momentum Signals - Xã Thanh Hà |
| 2025-10-07 | +4.6% | news | Seeking Alpha | KalVista: Prophylaxis Is Shrinking The Acute HAE TAM |
| 2025-10-07 | +4.6% | news | Seeking Alpha | KalVista: Prophylaxis Is Shrinking The Acute HAE TAM (NASDAQ:KALV) - Seeking Alpha |
| 2025-11-10 | +4.6% | earnings | Seeking Alpha | KalVista Pharmaceuticals GAAP EPS of -$0.92, revenue of $13.69M |
| 2025-11-10 | +4.6% | earnings | Seeking Alpha | KalVista Pharmaceuticals Q3 2026 Earnings Preview |
| 2025-11-10 | +4.6% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-11-10 | +4.6% | earnings | Yahoo Finance | KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2025-11-10 | +4.6% | news | Business Wire | KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results - Business Wire |
| 2026-01-15 | -4.4% | analyst | Yahoo Finance | Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - Yahoo Finance |
| 2026-04-20 | -4.3% | news | Stock Titan | Tax-driven RSU share sale by KalVista (KALV) CCO Nicole Sweeny - Stock Titan |
| 2026-04-20 | -4.3% | executive | Stock Titan | Tax-related share sale by KalVista (KALV) CEO after RSU vesting - Stock Titan |
| 2026-04-20 | -4.3% | news | Stock Titan | KalVista (KALV) CMO sells shares to cover RSU tax obligations - Stock Titan |
| 2026-04-20 | -4.3% | executive | Stock Titan | KalVista (KALV) CFO sells 1,862 shares to cover RSU tax obligations - Stock Titan |
| 2022-10-17 | -4.2% | legal | SEC EDGAR | KALV 8-K: 5.02, 5.07, 7.01 (SEC Filing) |
| 2025-09-25 | -4.2% | news | Seeking Alpha | KalVista prices upsized offering of $125M of 3.250% notes due 2031 |
| 2026-03-11 | -4.1% | analyst | Investor's Business Daily | KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86 - Investor's Business Daily |
| 2026-03-31 | +4.0% | news | Yahoo Finance | KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial - Yahoo Finance |
| 2026-03-31 | +4.0% | earnings | MarketBeat | Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat |
| 2026-04-08 | -4.0% | news | Business Wire | KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference |
| 2026-04-08 | -4.0% | news | Stock Titan | KalVista schedules April 15 webcast for Needham healthcare conference - Stock Titan |
| 2024-07-11 | +4.0% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2024-07-11 | +4.0% | earnings | InvestorPlace | KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 - InvestorPlace |
| 2022-12-21 | +4.0% | analyst | TradingView | KALV Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-07-15 | +3.8% | news | Seeking Alpha | KalVista gets UK nod for Ekterly |
| 2023-09-07 | -3.8% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2026-03-04 | +3.7% | news | Business Wire | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire |
| 2026-02-02 | +3.7% | earnings | Yahoo Finance | TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results - Yahoo Finance |
| 2026-02-02 | +3.7% | analyst | Yahoo Finance | Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade - Yahoo Finance |
| 2024-12-05 | +3.7% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2026-03-22 | -3.4% | news | Seeking Alpha | Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag |
| 2025-12-20 | +3.4% | news | Trefis | KalVista Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis |
| 2026-04-16 | -3.3% | expansion | MarketBeat | KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach |
| 2026-04-16 | -3.3% | earnings | MarketBeat | KalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 6.4% - Here's Why - MarketBeat |
| 2025-06-24 | -3.3% | legal | Seeking Alpha | FDA's Makary sought to reject KalVistas drug: report |
| 2026-03-24 | +3.0% | earnings | Seeking Alpha | KalVista Pharmaceuticals Q4 2025 Earnings Preview |
| 2025-04-13 | +3.0% | news | Intellectia AI | KALV Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2025-04-12 | +3.0% | news | Seeking Alpha | KalVista Stock: Poised For Rare Disease Transformation (NASDAQ:KALV) - Seeking Alpha |
| 2026-02-17 | +3.0% | news | Seeking Alpha | Most shorted stocks with up to $2B market cap as of mid-February (VB:NYSEARCA) - Seeking Alpha |
| 2023-01-05 | -2.9% | legal | SEC EDGAR | KALV 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-07-09 | +2.9% | news | simplywall.st | Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation - simplywall.st |
| 2025-07-09 | +2.9% | earnings | MarketBeat | KalVista Pharmaceuticals (KALV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat |
| 2026-01-09 | +2.8% | earnings | Seeking Alpha | KalVista reports $49M in 2025 Ekterly revenue, shares rise |
| 2026-01-09 | +2.8% | earnings | Trefis | KalVista Stock Pre-Market (+14%) : Reports Strong EKTERLY Launch Revenue - Trefis |
| 2021-07-13 | -2.8% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-08-21 | +2.7% | legal | SEC EDGAR | KALV 8-K: 8.01 (SEC Filing) |
| 2023-06-14 | -2.6% | legal | SEC EDGAR | KALV 8-K: 5.02, 5.03 (SEC Filing) |
| 2024-09-05 | -2.6% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2024-09-05 | -2.6% | news | Stock Titan | KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update - Stock Titan |
| 2024-09-05 | -2.6% | news | Seeking Alpha | KalVista Pharmaceuticals: Looking To Be A Major Player In HAE (NASDAQ:KALV) - Seeking Alpha |
| 2026-04-13 | +2.4% | news | simplywall.st | How Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data - simplywall.st |
| 2025-09-29 | -2.4% | legal | SEC EDGAR | KALV 8-K: 1.01, 2.03, 3.02, 8.01 (SEC Filing) |
| 2026-04-22 | -2.4% | earnings | UBND thành phố Hải Phòng | KALV (KalVista Pharmaceuticals Inc.) delivers massive Q4 2025 earnings beat, shares rise 4.7% on strong investor sentiment. - ROA - UBND thành phố Hải Phòng |
| 2026-04-22 | -2.4% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | KalVista Pharmaceuticals (KALV) Stock Fundamentals | Q4 2025: EPS Tops Views - Pricing Power - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2025-12-22 | +2.3% | news | Seeking Alpha | KalVista Pharmaceuticals approves EKTERLY (sebetralstat) in Japan |
| 2026-02-11 | +2.3% | news | Seeking Alpha | KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion |
| 2026-02-11 | +2.3% | news | Seeking Alpha | KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion (KALV) - Seeking Alpha |
| 2026-01-08 | +2.2% | legal | SEC EDGAR | KALV 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-08 | +2.2% | news | Stocktwits | KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart - Stocktwits |
| 2025-11-27 | +2.1% | earnings | Quiver Quantitative | KalVista Pharmaceuticals Stock (KALV) Opinions on Q3 Revenue Success - Quiver Quantitative |
| 2024-07-23 | -2.0% | legal | SEC EDGAR | KALV 8-K: 1.01 and 2.03 (SEC Filing) |
| 2026-04-01 | -2.0% | news | Simply Wall St. | KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial |
| 2025-09-08 | -1.8% | news | Seeking Alpha | KalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 Transcript |
| 2025-10-02 | -1.8% | legal | SEC EDGAR | KALV 8-K: 5.02, 5.07, 7.01 (SEC Filing) |
| 2021-07-31 | +1.7% | earnings | Zacks Investment Research | What date does KalVista Pharmaceuticals's (KALV) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2026-03-20 | +1.7% | news | Stock Titan | New angioedema drug data in children as young as 2 gets late-breaking slot - Stock Titan |
| 2024-06-24 | -1.7% | expansion | Seeking Alpha | KalVista: Sebetralstat Nears Approval, Aiming For 2025 Launch (NASDAQ:KALV) - Seeking Alpha |
| 2026-03-30 | +1.6% | news | MT Newswires | KalVista Pharmaceuticals Posts Positive Phase 3 Data For Pediatric Swelling Drug |
| 2026-03-30 | +1.6% | news | Business Wire | KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference |
| 2026-04-02 | +1.6% | news | Business Wire | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-02 | +1.6% | news | simplywall.st | A Look At KalVista Pharmaceuticals (KALV) Valuation After Positive KONFIDENT KID EKTERLY Trial Update - simplywall.st |
| 2026-04-02 | +1.6% | news | Business Wire | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire |
| 2022-05-27 | +1.5% | legal | SEC EDGAR | KALV 8-K: 5.02 (SEC Filing) |
| 2021-09-15 | +1.5% | legal | SEC EDGAR | KALV 8-K: 8.01 (SEC Filing) |
| 2024-03-26 | -1.2% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-11-24 | -1.1% | news | Seeking Alpha | KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript |
| 2026-04-03 | +1.0% | news | Seeking Alpha | Most and least shorted healthcare stocks with up to $2B market cap in March |
| 2022-09-08 | -0.8% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2025-03-12 | -0.6% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2021-12-09 | -0.6% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2021-09-09 | +0.6% | legal | SEC EDGAR | KALV 8-K: 2.02 and (SEC Filing) |
| 2026-04-06 | +0.6% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is KalVista Pharmaceuticals (KALV) Stock Stable Now | Price at $20.74, Up 4.22% - New Listings - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-06 | +0.6% | news | UBND thành phố Hải Phòng | Is KalVista Pharmaceuticals (KALV) Stock Stable Now | Price at $20.74, Up 4.22% - Quantitative Analysis - UBND thành phố Hải Phòng |
| 2025-12-09 | -0.6% | news | simplywall.st | Possible Bearish Signals With KalVista Pharmaceuticals Insiders Disposing Stock - simplywall.st |
| 2024-03-07 | -0.5% | legal | SEC EDGAR | KALV 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-12-16 | -0.5% | legal | SEC EDGAR | KALV 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-02-16 | +0.4% | news | Seeking Alpha | Most and least shorted healthcare stocks with up to $2B market cap - Seeking Alpha |
| 2025-11-03 | -0.4% | news | Business Wire | KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 - Business Wire |
| 2026-02-25 | -0.3% | news | Stock Traders Daily | How Kalvista Pharmaceuticals Inc. (KALV) Affects Rotational Strategy Timing - Stock Traders Daily |
| 2026-02-25 | -0.3% | news | Investing.com Nigeria | KalVista Pharma CCO Sweeny Sold $61,878 in Stock By Investing.com - Investing.com Nigeria |
| 2026-02-24 | -0.3% | analyst | Yahoo Finance | Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet - Yahoo Finance |
| 2025-04-25 | +0.2% | news | Stock Titan | KALV Stock Price, News & Analysis | Kalvista Pharm - Stock Titan |
| 2026-04-23 | -0.0% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | KalVista Pharmaceuticals (KALV) Stock Fundamentals | Q4 2025: EPS Tops Views - Dividend Initiation - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-08-18 | +0.0% | news | Quiver Quantitative | KALV | KalVista Pharmaceuticals, Inc. Common Institutional Ownership - Quiver Quantitative |
| 2024-11-26 | -0.0% | legal | SEC EDGAR | KALV 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-02-02 | +0.0% | analyst | eToro | KALV Stock Price | Analyst Target 36.17 & Consensus - eToro |
| 2026-04-26 | — | earnings | MarketBeat | KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat |